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IntroductIon
Type 2 diabetes (T2D) encompasses a heterogeneous 
group of metabolic disorders characterized by varying 
degrees of insulin resistance, impaired insulin secretion 
and increased glucose production1.
According to the World Confederation for com-
bating diabetes, there has been a dramatic increase 
in the prevalence of the disease over the last two de-
cades, while the number of patients is expected to rise 
worldwide from 171 million in 2000 to 336 million in 
20302. The increasing prevalence of type 2 diabetes 
worldwide is attributed to aging, population growth, 
urbanization and the increasing prevalence of obesity 
and physical inactivity2. In addition, there is compel-
ling evidence that genetic factors make a major contri-
bution to the development of T2D. Indeed, nowadays, 
type 2 diabetes is best described as a multifactorial 
trait in which multiple genetic and environmental 
factors interplay in complex and non-linear ways to 
produce the common phenotype of hyperglycemia. 
Understanding the genetic component of T2D patho-
genesis will facilitate its treatment, diagnosis and 
prevention3,4.
Over the past two decades, extensive research ef-
forts have taken place in order to identify the genetic 
variants that contribute to individual differences in 
predisposition to T2D. However, until recently, these 
efforts were characterized by slow progress and lim-
ited success. Until 2006, the main approaches used to 
identify common genetic variants influencing common 
dichotomous traits, such as T2D, were linkage analysis 
and candidate gene studies. Both approaches suffered 
from certain limitations and neither of them proved 
particularly successful in detecting robustly replicat-
ing T2D-associated loci. The first approach suffered 
from being underpowered because linkage analysis is 
best placed to detect variants with high penetrance. 
Thus far, there is no evidence that common variants 
with high penetrance make a substantial contribution 
to the risk of common forms of T2D. The second ap-
proach had difficulties mainly associated with choos-
ing credible gene candidates. For the purposes of a 
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candidate gene study, the selection of genes was typi-
cally based on hypotheses about probable biological 
mechanisms involved in T2D pathogenesis. However, 
the poor characterisation of the function of much of 
the genome rendered the selection of candidate genes 
difficult. In addition, poor understanding of the archi-
tecture of genetic variation, low-throughput genotyp-
ing platforms available at the time, the small sample 
sizes deployed and the use of liberal thresholds for 
declaring significance were some of the factors that 
hindered candidate-gene approaches from identifying 
reproducibly associated T2D variants5-7.
Hence, until 2006, only two of the many T2D-
associated variants reported by candidate gene stud-
ies had been convincingly replicated: the Pro12Ala 
and Glu23Lys variants in PPARG and KCNJ11 genes 
respectively8,9. The protein encoded by the PPARG 
(peroxisome proliferator-activated receptor gamma) 
gene is a regulator of adipocyte differentiation and 
represents the target for the thiazolidinedione class of 
drugs used to treat T2D10,11. The KCNJ11 (potassium 
inwardly-rectifying channel, subfamily J, member 
11) gene encodes a subunit of an inwardly rectifying 
ATP-sensitive potassium channel. In pancreatic beta 
table 1. GWA scans for type 2 diabetes included in this reviewª.
Study Yearpublished
Initial
sample source
number of
cases/controls Genotyping platform refs
Diabetes Gene Discovery 
Group
1st stage by Sladek et al.
2007 France 694 cases/669 controls
Illumina Human-1
Illumina HumanHap300 (20)
deCODE Genetics 2007 Iceland 1399 cases/5275 controls Illumina HumanHap300 21)
Wellcome Trust Case Control 
Consortium (WTCCC) 2007 UK
1924 cases/2938 
controls
Affymetrix SNP  
Array 5.0 (22)
Diabetes Genetics Initiative 
(DGI) 2007
Finland
Sweden
1464 cases/1467 
controls 
Affymetrix  
SNP Array 5.0 (23)
Finland-US investigation of 
NIDDM Genetics  (FUSION) 2007 Finland
1161 cases/1174 
controls
Illumina  
HumanHap300 (24)
DiaGen 2007
East Finland, 
Germany, UK, 
Ashkenazi 
500 cases/497 
controls
Illumina  
HumanHap300 (25)
BioBank Japan 2008 Japanese 194 cases/1556 controls
Custom set  
of 268k SNPs (26)
Takeuchi et al. 2009 Japanese 519 cases/503 controls
Illumina  
HumanHap550 (27)
Diabetes Gene Discovery 
Group
2nd stage by Rung et al.
2009 France 679 cases/697 controls
Illumina Human-1
Illumina HumanHap300 (28)
HanChinese 2010 Chinese 995 cases/894 controls
Illumina  
HumanHap550 (29)
ªStudies are listed in ascending order of publication.
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cells, these channels are crucial for the regulation 
of glucose-induced insulin secretion and are the tar-
get for the sulfonylureas10,11. The strongest, thus far, 
known association with T2D was identified in 2006 
through linkage fine-mapping study on chromosome 
1012. It resides within TCF7L2 (transcription factor 7 
like 2) gene and has been replicated in multiple pop-
ulations13-18.
Over the past three years, the advent of genome-
wide association (GWA) scan has ushered in a new era 
regarding the capacity of identifying common genetic 
variants that contribute to predisposition to complex 
multifactorial phenotypes such as type 2 diabetes. The 
implementation of the GWA approach was the result 
of three components: 1) the development of high-
throughput genotyping platforms that enabled the 
conduct of massive SNP typing at high accuracy and 
low cost, 2) the availability of large sample collections 
which enhanced power in association studies and 3) a 
better understanding of patterns of sequence variation 
resulting from international efforts such as the Human 
Genome Sequencing Project and the HapMap19. 
GWA scans for type 2 diabetes
For the purposes of this review, we examined GWA 
scans that have genotyped over 150,000 SNPs. We 
found ten such GWA studies (20-29): seven conducted 
in European populations, two conducted in Japanese 
population and one carried out in a Han Chinese popu-
lation (Table 1). Moreover, a meta-analysis of three 
such GWA scans, which is in fact the first of its kind, 
is reported in this paper (30). Five GWA scans31-35 that 
have genotyped less than 150,000 SNPs were not in-
cluded (Table 2).
Common features of most of the studies reported 
in this paper are the case-control study design and the 
employment of commercially available, fixed content 
genotyping platforms. Other aspects such as the spe-
cific populations examined, sample size and ascer-
tainment, the extent to which cases and controls were 
matched and follow-up strategies differ among stud-
ies. 
The first published GWA study for T2D was con-
ducted by Sladek et al.20. In particular, the Diabetes 
Gene Discovery Group undertook a two-stage GWA 
scan, the fist one performed by Sladek et al. and the 
second by Rung et al. In the first stage of the study, 
392,935 SNPs were genotyped in 694 T2D cases and 
669 controls from France. Genotypes for each study 
subject were obtained using two platforms: Illumina 
Human-1 to assay SNPs chosen using a gene-centred 
design and Illumina HumanHap300 to assay SNPs 
chosen to tag haplotype blocks identified by the Phase 
1 Hap Map. Selection criteria such as family his-
tory of at least one affected first degree relative, age 
at onset under 45 years and body mass index (BMI) 
< 30 Kg/m2 were chosen for the diabetic subjects in 
order to decrease phenotypic heterogeneity and en-
rich for variants that determine insulin resistance and 
β-cell dysfunction through mechanisms other than se-
vere obesity. Because of unequal male/female ratios 
in cases and controls, 12,666 X-linked SNPs were 
separately analyzed for each gender, however none 
of them attained significance. In total, 59 autosomal 
table 2. GWA scans for type 2 diabetes not included in this reviewª.
Study Year published
Initial
sample source
number of 
cases/controls
Genotyping  
platform refs
Hanson et al. 2007 Pima Indians 300 cases/334 controls Affymetrix 100k (31)
Hayes et al. 2007 Mexican Americans 281 cases/280 controls Affymetrix 100k (32)
Rampersaud et al 2007 Amish 124 cases/295 controls Affymetrix 100k (33)
Florez et al. 2007 Massachusetts 91 cases/1087 controls Affymetrix 100k (34)
Yasuda et al. 2008 Japanese 187 cases/1504 controls JSNP 100k SNPs (35)
ªStudies are listed in ascending order of publication.
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SNPs showing significant association at stage 1 were 
genotyped in a bigger sample of 2,617 T2D cases 
and 2,894 controls. The study confirmed the previ-
ously known association of TCF7L2 (rs7903146; 
OR = 1.65 ± 0.19) and identified significant associa-
tions for 7 SNPs representing four novel T2D sus-
ceptibility loci: SLC30A8 (rs13266634; OR = 1.18 
± 0.25), HHEX/IDE (rs7923837; OR = 1.22 ± 0.21), 
LOC387761 (rs7480010; OR = 1.14 ± 0.13) and EXT2 
(rs11037909; OR = 1.27 ± 0.30).
Four further GWA studies were published shortly 
afterwards21-24. Steinthorsdottir et al.21 using Illumina 
Human-1 genotyped 313,179 SNPs in a sample of 
1,399 T2D cases and 5,275 controls from Iceland. 
In addition, 339,846 two-marker haplotypes were 
tested. The previously identified SNP, rs7903146, 
in TCF7L2 gave the most significant results with 
OR = 1.38 and P = 1.82x10-10 in all individuals with 
type 2 diabetes, whereas no other SNP or haplotype 
was significant after adjustment for the number of 
tests performed. In total, 51 SNPs (single SNPs and 
two-marker haplotypes with P < 0.00005) were se-
lected for replication in a sample of 1,110 T2D cas-
es and 2,272 controls from Denmark. In the Danish 
group of T2D cases, two SNPs were significantly 
associated: rs7756992 and rs13266634 (OR = 1.24, 
P = 0.00013 and OR = 1.20, P = 0.0012 respective-
ly). These SNPs were additionally genotyped in three 
other T2D case-control groups of European ancestry 
from Denmark, the Netherlands and Philadelphia (of 
total sample size 3,836 cases and 12,562 controls) as 
well as in case-control groups from Hong Kong (1,457 
cases/986 controls) and West Africa (865 cases/1.106 
controls). The SNP rs7756992 in the CDKAL1 gene 
was associated with T2D in individuals of European 
ancestry (OR = 1.20, P = 7.7x10ˉ9) and individuals 
from Hong Kong of Han Chinese ancestry (OR = 1.25, 
P = 0.00018). In conclusion, the deCODE study con-
firmed the previously known association of TCF7L2 
gene with T2D and identified CDKAL1 as new T2D-
susceptibility locus.
The CDKAL1 locus was independently identified 
by three further contemporaneous studies performed 
by the Wellcome Trust Case Control Consortium 
(WTCCC), Diabetes Genetics Initiative (DGI) and 
Finland-United States Investigation of NIDDM ge-
netics (FUSION)22-24. These three studies collaborated 
by sharing data with respect to replication stage and 
therefore in this paper we present the findings of their 
shared efforts. WTCCC22 is a joint GWA scan of 7 
common diseases: bipolar disorder, coronary artery 
disease, hypertension, Crohn’s disease, rheumatoid ar-
thritis, type 1 diabetes and type 2 diabetes. The study 
was conducted in the British population using groups 
of ~2,000 cases for each of the 7 examined diseases 
and a shared group of ~3,000 controls. The genotyp-
ing platform, Affymetrix SNP array 5.0, was used to 
genotype a total number of 469,557 SNPs. The group 
of T2D cases was comprised of 1,924 individuals 
while the control group was comprised of 2,938 indi-
viduals from the UK. In order to decrease the pheno-
typic heterogeneity of T2D the researchers employed 
selection criteria such as: British/Irish ancestry, fam-
ily history of type 2 diabetes and age at onset under 
65 years. The study identified 24 independent associa-
tion signals for the seven diseases examined, of which 
three were association signals for T2D: TCF7L2, FTO 
and CDKAL1. The DGI23 study employed the same 
genotyping platform, Affymetrix SNP array 5.0, and 
successfully genotyped 386,731 SNPs in 1,464 T2D 
cases and 1,467 controls from Finland and Sweden. 
In addition, 284,968 haplotypes were examined. Case 
and control groups were matched for sex, age, BMI 
and place of origin.  107 SNPs were selected for rep-
lication in a sample of 10,850 individuals (cases and 
controls) from Sweden, Poland and U.S.A. Scott et 
al24, using the genotyping platform Illumina Human-
Hap 300, assayed 317,503 SNPs in 1.161 T2D cases 
and 1,174 controls from Sweden. From the first stage 
of the study, 82 SNPs were chosen (after comparison 
with WTCCC and DGI studies) for replication in 1,215 
T2D cases and 1,258 controls. The shared efforts of 
these three GWA scans resulted in the identification 
of three new T2D-susceptibility loci: CDKN2A/2B 
(rs10811661; OR = 1.20, CI = 1.14-1.25, P = 7.8 x 
10-10), FTO (rs8050136; OR = 1.17, CI = 1.12-1.22, 
P = 1.3 x 10ˉ¹²) and IGF2BP2 (rs4402960; OR = 1.14, 
CI = 1.11-1.18, P = 8.9x10-10). Furthermore, the as-
sociation of previously reported loci with T2D was 
confirmed: PPARG (rs1801282), KCNJ11 (rs5219), 
TCF7L2 (rs7903146) and CDKAL1 (rs7754840).
Salonen et al25, using the genotyping platform Il-
lumina HumanHap300, genotyped almost 300,000 
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SNPs in 500 cases of T2D and 497 controls originat-
ed from four different populations. In particular, the 
study was conducted in 200 cases and 200 controls 
from Eastern Finland, 200 cases and 197 controls 
from Israel and finally 99 cases and 100 controls from 
Germany and England. The phenotypic heterogeneity 
of T2D cases was restricted using selection criteria 
such as: family history of T2D and age at onset under 
60 years. Initially, 315,917 SNPs were genotyped in 
the sample mentioned above, whereas in the replica-
tion study, 10 SNPs showing the strongest statistically 
significant association where chosen to be genotyped 
in a sample of 2,573 T2D cases and 2,776 controls. It 
should be noted that this replication study sample was 
the same one used for replication by Sladek et al. The 
study confirmed the previously known association of 
the rs7903146 SNP in TCF7L2 gene but, mainly due 
to restricted power failed to identify any novel T2D 
association signals. 
Unoki et al.26 performed the first GWA scan in a 
population of non European descent. In particular, 
207,097 SNPs that cover more than 50% of common 
SNPs in the Japanese were successfully genotyped in 
194 cases with T2D and diabetic retinopathy and in 
1,558 controls. Subsequently, 8,323 SNPs with the 
highest levels of significance were genotyped in 1,367 
individuals with T2D and diabetic retinopathy and in 
1,266 controls. Of 6,731 SNPs for which data were 
obtained successfully, the researchers selected 9 SNPs 
(p < 0.0001) and genotyped them in a third set of cases 
and controls comprised of 3,557 Japanese individuals 
with T2D and 1,352 controls. The study confirmed the 
association of the CDKAL1 and IGF2BP2 loci and ad-
ditionally identified KCNQ1 (rs2283228, OR = 1.26, 
95% CI = 1.18-1.34) as a novel T2D susceptibility lo-
cus. A smaller GWA study performed in the Japanese 
by Yasuda et al.35, also identified KCNQ1 as T2D sus-
ceptibility locus.
Takeuchi et al27 performed a three-staged genome-
wide association study in the Japanese population. 
Using Illumina HumanHap 550, a total number of 
482,625 SNPs was successfully genotyped in 519 T2D 
cases and 503 controls. Subsequently, 1,456 SNPs 
were genotyped in the second stage sample comprised 
of 1,110 T2D cases and 1,014 controls. At this stage, 
30 SNPs representing 17 unique loci attained signifi-
cance (defined as p < 7 x 10-9). One SNP of each of 
these 17 loci was selected for typing in the third stage 
sample of the study comprised of 4,000 T2D cases 
and 4,889 controls. Genome-wide significant associa-
tion was revealed for three previously reported loci: 
CDKAL1 (rs4712523; OR = 1.27, CI = 1.21-1.33, 
P = 7.2 x 10-20), CDKN2A/CDKN2B (rs2383208; 
OR = 1.34, CI = 1.27-1.41, P = 2.1 x 10-20) and KC-
NQ1 (rs2237892; OR = 1.33, CI = 1.27-1.41, P = 1.1 
x 10-20).
The second stage of Diabetes Genes Discovery 
study, performed by Rung et al28 (the first one was 
performed by Sladek et al), was recently published. 
Of 392,365 SNPs that were initially genotyped in a 
total sample of 1,376 individuals from France, the re-
searchers selected 16,273 SNPs and genotyped them 
in 2,245 T2D cases and in 2,732 controls from France. 
Subsequently, 28 SNPs were chosen for replication 
study in 7,698 Danish individuals comprised of 3,334 
T2D cases and 4,364 controls. The study confirmed 
the association of the previously reported loci TC-
F7L2 (rs7903146), CDKAL1 (rs4712523) and WFS1 
(rs4689388), and identified one SNP (rs2943641; 
OR = 1.19, CI = 1.13-1.25) located adjacent to IRS1 
gene as a novel T2D-susceptibility loci.
The last to date published GWA scan was conducted 
in a Han Chinese population residing in Taiwan. Tsai et 
al.29 undertook a two-stage genome-wide association 
study, in which 995 T2D cases and 894 controls were 
genotyped using the Illumina HumanHap550 chip 
for the first genome scan stage. In this stage, high-
quality genotypes were obtained for 517,737 SNPs. 
Subsequently, 39 SNPs were selected for replication 
in 1,803 T2D cases and 1,473 controls in stage 2. The 
study confirmed the association of KCNQ1 gene with 
T2D risk (rs2237895; OR = 1.29, CI = 1.19-1.40, 
P = 9.65 x 10-10) and identified two novel T2D sus-
ceptibility loci: PTPRD (rs17584499; OR = 1.57, 
CI = 1.36-1.82, P = 8.54 x 10-10) and SRR (rs391300; 
OR = 1.28, CI = 1.18-1.39, P = 3.06 x 10-9). Both PT-
PRD and SRR genes have not been associated to T2D 
in previous GWA scans and need further replication in 
additional populations. 
Meta-Analysis of three GWA scans for type 2 diabe-
tes
Although GWA scans constitute the present state-of-
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the-art in efforts of elucidating the genetic component 
of complex diseases, they still face limitations regard-
ing the power of individual studies to detect common 
SNPs with small or modest effects. Statistical power 
can be enhanced through the combination of datasets 
and through the concomitant examination of both di-
rectly genotyped and imputed SNPs7,19. SNPs that are 
directly genotyped are typically analysed by single-
point methods19. Imputation approaches, on the other 
hand, are multipoint methods that take into account 
information from multiple surrounding markers and 
can detect SNPs that have not been directly typed36. 
Hence, imputation allows the examination of more 
than 2 million genetic markers genome-wide in par-
allel and moreover enables the combination of data 
from GWA scans carried out on different genotyping 
platforms19,36.
The DIAGRAM Consortium (Diabetes Genetics, 
Replication And Meta-Analysis) is the first complex 
disease GWA scan meta-analysis conducted by Zeg-
gini et al (30). DIAGRAM combined data across 
4,549 T2D cases and 5,579 controls, all of Europe-
an descent, from the studies WTCCC, DGI and FU-
SION. The genotyped autosomal SNPs that passed 
quality control filters in each study were: a) 393,143 
SNPs from the Affymetrix SNP Array 5.0 in WTCCC 
(MAF > 0.01, 1,924 T2D cases and 2,938 controls), 
b) 378,860 SNPs from the Affymetrix SNP Array 5.0 
in DGI (ΜΑF > 0.01, 1,464 T2D cases and 1,476 con-
trols) and c) 306,222 SNPs from the Illumina Human-
Hap300 in FUSION (MAF > 0.01, 1,161 T2D cases 
and 1.174 controls). There were 44,700 SNPs directly 
genotyped in all three studies across the two platforms. 
In addition, 1,570,311 SNPs were imputed in each 
sample resulting in the final examination of 2,202,892 
variants across a total sample of 10,128 individuals. 
Sixty nine SNPs showing the strongest associations 
(meta-analysis p value < 10−4 and meta-analysis het-
erogeneity p value > 10−4), were selected for replica-
tion in 22,426 individuals of European descent. The 
top 11 signals (p < 10−5) emerging from this second 
stage were further genotyped in 57,366 individuals of 
European descent in stage 3. 
After integrating data from all three stages of the 
meta-analysis, six signals reached genome-wide sig-
nificance levels (p ≤ 5 x 10−8) for T2D association: 
JAZF1 (OR = 1.10, CI = 1.07-1.13), CDC123/CAM-
K1D (OR = 1.11, CI = 1.07-1.14), TSPAN8/LGR5 
(OR = 1.09, CI = 1.06-1.12), THADA (OR = 1.15, 
CI = 1.10-1.20), ADAMTS9 (OR = 1.09, CI = 1.06-
1.12), and NOTCH2 (OR = 1.13, CI = 1.08-1.17). 
The genetic component of T2D pathogenesis: knowl-
edge gained
Thus far, the literature counts 18 robustly replicat-
ing T2D-susceptibility loci (Table 3). Susceptibility 
loci are selected on the basis of their colocalization 
to the same interval as an association signal. How-
ever, colocalization does not prove causation because 
genetic variants may be exerting their influence on 
T2D pathogenesis through regulatory effects on genes 
whose coding sequences lie some distance away. That 
is the case with several of the T2D-associated signals 
that map to ‘gene deserts’, whereas others map to re-
gions containing good candidates, such as SLC30A8 
and HHEX/IDE genes37. In addition, the task of mov-
ing from an association signal to mechanistic insights 
is difficult and requires identification of the causative 
variants through resequencing, fine-mapping and 
functional studies. Hence, early inferences regarding 
etiopathological mechanisms should be cautious and 
it should be expected that occasionally, genes other 
than the regional candidates might prove out to be re-
sponsible for the susceptibility effect37, 5.
Most of the T2D-associated signals identified 
to date (involving SNPs within or adjacent to KC-
NJ11, HNF1B, SLC30A8, HHEX/IDE, CDKAL1, 
CDKN2A/B, IGFBP2, JAZF1 and TCF7L2) appear 
to exert their primary effect on diabetes pathogen-
esis through disruption of insulin secretion7. This is 
consistent with growing evidence supporting the sub-
stantial role of defects in β-cell function and mass in 
the development of diabetes38 and it could be stated 
that the inherited component of T2D predisposition is 
predominantly characterized by alterations of β-cell 
function and mass37. However, we should also consid-
er that the genetic variants identified thus far account 
for only a small proportion of the overall genetic risk 
of the disease. Moreover, selection criteria employed 
by several GWA studies, such as lean T2D cases, may 
have generated bias against the detection of variants 
affecting insulin action37.
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table 3. Summary of confirmed T2D-associated loci and SNPsª.
Locus/gene chr  Index SnP* Position 
Effect 
size  
**
risk-allele
frequency 
**
Year  
association
identified
Study type  
Probable  
mechanism
PPARG 3 rs1801282 12368125 1.14 0.87 2000 Candidate gene Insulin action
KCNJ11 11 rs5219 17366148   1.15 0.40 2003 Candidate gene
β-cell  
dysfunction
TCF7L2 10 rs7901695 114744078 1.37 0.31 2006
Linkage peak 
fine-mapping
β-cell  
dysfunction
HHEX/IDE 10 rs5015480 94455539 1.13 0.63 2007 GWA
β-cell  
dysfunction
SLC30A8 8 rs13266634 118253964 1.15 0.69 2007 GWA
β-cell  
dysfunction
CDKAL1 6 rs10946398 20769013 1.14 0.32 2007 GWA
β-cell  
dysfunction
FTO 16 rs8050136 52373776 1.17 0.40 2007 GWA Altered BMI
CDKN2A/B 9 rs10811661 22124094 1.20 0.83 2007 GWA
β-cell  
dysfunction
IGF2BP2 3 rs4402960 186994381 1.14 0.32 2007 GWA
β-cell  
dysfunction
HNF1B  
(TCF2)
17 rs757210 33170628 1.08 0.43 2007
Large-scale  
association
β-cell  
dysfunction
WFS1 4 rs10010131 6343816 1.12 0.60 2007
Large-scale  
association
Unknown
KCNQ1 11 rs2237892 2796327 1.29 0.93 2008 GWA
β-cell  
dysfunction
JAZF1 7 rs864745 28147081 1.10 0.50 2008
GWA   
meta-analysis
β-cell  
dysfunction
CDC123/
CAMK1D
10 rs12779790 12368016 1.11 0.18 2008
GWA 
meta-analysis
Unknown
TSPAN8/
LGR5
12 rs7961581 69949369 1.09 0.27 2008
GWA 
meta-analysis
Unknown
tHAdA 2 rs7578597 43586327 1.15 0.90 2008
GWA 
meta-analysis
Unknown
AdAMtS9 3 rs4607103 64686944 1.09 0.76 2008
GWA 
meta-analysis
Unknown
notcH2 1 rs10923931 120319482 1.13 0.10 2008
GWA 
meta-analysis
Unknown
ªData populating this table are derived through refs 5, 7 and 37. 
*A representative SNP with strong statistical significance is presented for each of these loci, because the true causal variants 
have not yet been identified.
**Effect size (estimated as per allele odds ratios) and risk allele frequencies are calculated in European populations.
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A compelling candidate for type 2 diabetes patho-
genesis is SLC30A8 (solute carrier family 30, member 
8) gene. This gene encodes a zinc transporter (ZnT8) 
which is expressed solely in pancreatic islets of 
Langerhans and colocalizes with insulin in the secre-
tory pathway granules of the insulin-secreting INS-1 
cells. ZnT8 knockout mice showed normal glucose 
tolerance and insulin sensitivity when fed on a control 
diet. However, after high-fat diet feeding the mice be-
came glucose intolerant or diabetic. These data show 
that ZnT8 transporter is essential for the formation of 
insulin crystals in beta cells, contributing to the pack-
aging efficiency of stored insulin39. Overexpression 
of SLC30A8 in insullinoma cells increases glucose-
stimulated insulin secretion40. On chromosome 10, 
the association signal maps to a region that contains 
the coding sequences of two strong candidates: HHEX 
and IDE genes5. The protein encoded by the HHEX 
(hematopoietically expressed homeobox) gene is a 
member of the homeobox family of transcription fac-
tors, many of which are involved in developmental 
processes10,11. HHEX has been implicated in pancreas 
development and the regulation of insulin secretion41. 
This gene, as well as TCF7L2, is involved in the regu-
lation of Wnt-signalling, indicating that dysfunction 
of this pathway may contribute to the development of 
diabetes7. IDE (insulin-degrading enzyme) gene codes 
for a zinc metallopeptidase that degrades intracellular 
insulin, and thereby terminates insulin’s activity10,11.
At least four of the T2D-associated signals map to 
regions (CDKAL1, CDKN2A/B, CDC23 and KCNQ1) 
that are thought to be involved in cell cycle regula-
tion7. The function of the protein encoded by CDKAL1 
[cyclin-dependent kinase 5 (CDK5) regulatory sub-
unit associated protein 1-like 1] gene has not yet been 
identified. However, this protein product is similar to 
CDK5 regulatory subunit associated protein 1, which 
has been implicated in the loss of β-cell function un-
der conditions of stimulation by high glucose42. The 
CDKN2A and CDKN2B genes encode cyclin-depen-
dent kinase inhibitors that are involved in cell-cycle 
regulation in the β-cell. Transgenic mice with over-
expression of the CDKN2A demonstrated decreased 
islet proliferation after exposure to a specific β-cell 
toxin. These data demonstrate that altered expression 
of the gene recapitulates the T2D phenotype43. 
Two of the reported T2D-susceptibility loci, WFS1 
and HNF1B, have emerged from large scale associa-
tion studies. WFS1 (Wolfram syndrome 1) gene is 
highly expressed in brain, pancreas, heart, and insulli-
noma beta-cell lines and encodes for a transmembrane 
protein, which is located primarily in the endoplasmic 
reticulum10,11. Mutations in this gene are associated 
with Wolfram syndrome, an autosomal recessive dis-
order, featured by diabetes insipidus, diabetes melli-
tus, optic atrophy and deafness44. Hepatocyte nuclear 
factor 1 homeobox B (HNF1B) gene, also known as 
TCF2, encodes a transcription factor which is involved 
in the development of embryonic pancreas. Mutations 
in this gene cause monogenic forms of diabetes45. 
Apart from these genes, two other T2D-associated 
loci are also known to harbour rare mutations that are 
causal for monogenic forms of diabetes: PPARG46 and 
KCNJ1147.
Finally, several of the genes and variants associ-
ated with T2D susceptibility appear to influence pre-
disposition to other common disease traits as well. 
Thus, variation in CDKAL1 has been revealed to have 
effect on susceptibility to Crohn’s disease48, variants 
at HNF1B and JAZF149,50 have been associated to 
prostate cancer, whereas the CDKN2A and CDKN2B 
genes are also known to play a role in the develop-
ment of cancer51. These pleiotropic effects might in-
dicate overlap in pathogenetic pathways, though in 
some cases, the pleiotropic relationships cross the ac-
cepted boundaries of comorbidity7.
dIScuSSIon
The discipline of molecular genetics has always been 
driven by the force of gaining novel biological in-
sights. A crucial step towards this direction is the iden-
tification of genes implicated in disease pathogenesis. 
From this perspective, GWA studies turned out to be 
the most fruitful approach in efforts of elucidating 
variants and genes that predispose to complex disease 
traits such as T2D. However the road ahead in T2D 
genetics is still long.
The 18 T2D-susceptibility loci identified to date, 
harbor common genetic variants with modest effect 
sizes5-7,37. As table 3 attests, the risk allele frequency 
of the representative genetic variants ranges from 
0.10 to 0.93. Per-allele effect sizes range from 1.08 to 
1.29, with the exception of the TCF7L2 gene where 
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the strongest association signal has been reported with 
per-allele effect size of 1.37. These spectrums of risk 
allele frequencies and effect sizes are typical of what 
is observed in GWA scans for other complex multi-
factorial diseases52. Less than 12 genetic variants as-
sociated with complex diseases, have been detected 
thus far having high effect size ranging from 2 to 1052. 
Hence, it is indicated that only a limited amount of 
the genetic variance predisposing to complex traits 
has been identified so far. In the case of T2D, the 18 
known variants explain less than 4% of the inherited 
predisposition, which implies that many more genes 
contributing to T2D predisposition remain to be dis-
covered53. Assuming that the undiscovered variants 
are of the same genetic architecture with those identi-
fied to date, then more than 800 of such genetic vari-
ants will be needed in order to explain 40% of T2D 
heritability53.
The missing heritability of T2D is assumed to lie 
in rare variants with intermediate penetrance, as well 
as structural variants54,7. Rare variants are likely to 
have larger effect sizes than those of common variants 
and might be population specific52. The GWA scans 
performed thus far have focused on the detection of 
susceptibility effects attributable to common SNPs 
and even with high density platforms, a proportion of 
such variants remains undetected. Currently employed 
genotyping arrays offer limited power to detect rare 
and structural variants and next-generation technolo-
gies are expected to address these challenges54. 
For the majority of the genetic variants associated 
with T2D thus far, the identified association remains 
probabilistic and not causal. Extensive resequenc-
ing, fine-mapping and functional studies are required 
in order to identify the causative variants and de-
fine the molecular mechanisms through which they 
function52,5. Gene redundancy, functional overlap of 
genes and gene-environment interactions render the 
identification of the truly causative variants difficult. 
In addition, we have limited knowledge of the extent 
to which epigenetic effects might mimic genetic pre-
disposition7. 
In summary, future steps in type 2 diabetes re-
search, include: a) the identification of new SNP as-
sociations with the conduct of GWA scans in different 
populations and enlarged meta-analyses, b) the detec-
tion of rare and structural variants contributing to T2D 
risk, c) the definition of causative variants and d) the 
conduct of animal or cellular studies in order to under-
stand the function of causative variants54, 5. 
The knowledge to be gained through these efforts 
is expected to affect the management of T2D. In the 
short term, new insights in molecular pathways impli-
cated in T2D pathogenesis are expected to reveal new 
therapeutic targets. The second clinical translation of 
this knowledge lies in the ability of using genetic vari-
ants as tools for predicting individual disease risk and 
response to drugs. The major challenge in T2D genet-
ics is to establish how the knowledge derived from 
T2D predisposing variants can be used to improve the 
care of the diabetic patient37,52.
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